SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended					1 Months Ended	3 Months Ended	6 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2009	Mar. 31, 2014 Protalix Bio Therapeutics Incorporation [Member]	Mar. 31, 2014 Pfizer Incorporation [Member]	Jun. 18, 2013 Protalix Ltd. [Member]	Dec. 31, 2009 Upon Filing of Pediatric Investigation Plan to EMA [Member]	Jun. 30, 2012 Upon FDA Approval [Member]
Significant Accounting Policies [Line Items]
Number of Subsidiaries	2
Pfizer Agreement, upfront payment received			$ 60,000				$ 5,000
Milestone payment triggered								25,000
Pfizer Agreement, future revenues and expense sharing percentage				40.00%	60.00%
Supply commitment for entitled rights to be received						280,000
License and supply agreement potential future payment						12,500
Supply agreement maximum consideration payment						40,000
Revenue from sale of products	$ 3,500
Common stock, par value per share	$ 0.001	$ 0.001
Options to purchase common stock not included in diluted LPS because the effect would be anti-dilutive	18,913,153	7,471,571